Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Everolimus + Vorolanib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Everolimus | Afinitor | RAD001|Zortress | mTORC1 Inhibitor 8 | Afinitor (everolimus) binds to FKBP-12 and allosterically inhibits mTOR, leading to decreased mTORC1 signaling and potentially resulting in decreased tumor cell growth (PMID: 17766661, PMID: 28400999). Afinitor (everolimus) is FDA approved for use in neuroendocrine tumors of pancreatic, lung or gastrointestinal tract origin, advanced renal cell carcinoma, in adult and pediatric patients aged 1 year and older with tuberous sclerosis complex who have subependymal giant cell astrocytoma, and in combination with Aromasin (exemestane) in hormone receptor-positive, HER2-negative breast cancer (FDA.gov). |
Vorolanib | X-82|CM-082|CM082 | PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 32 | Vorolanib (X-82) is a dual VEGFR/PDGFR inhibitor, which inhibits tumor angiogenesis and cell proliferation in tumors (PMID: 32335374, PMID: 30478190). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | renal cell carcinoma | not applicable | Everolimus + Vorolanib | Phase I | Actionable | In a Phase I trial, combination of Vorolanib (X-82) and Afinitor (everolimus) resulted in partial response in 2 patients and stable disease in 1 patient with renal cell carcinoma (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588). | detail... |
Unknown unknown | clear cell renal cell carcinoma | not applicable | Everolimus + Vorolanib | Phase I | Actionable | In a Phase I trial, Vorolanib (X-82) and Afinitor (everolimus) combination therapy was well tolerated, and resulted in an objective response rate of 32% (6/19) and a disease control rate of 100% in patients with advanced clear cell renal cell carcinoma, with a median progression-free survival of 5.6 months (PMID: 32335374; NCT03095040). | 32335374 |
Unknown unknown | Advanced Solid Tumor | not applicable | Everolimus + Vorolanib | Phase I | Actionable | In a Phase I trial, combination of Vorolanib (X-82) and Afinitor (everolimus) resulted in partial response in 9.5% (2/21) and stable disease in 57.1% (12/21) of patients with advanced solid tumors (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588). | detail... |
Unknown unknown | glioblastoma | not applicable | Everolimus + Vorolanib | Phase I | Actionable | In a Phase I trial, combination of Vorolanib (X-82) and Afinitor (everolimus) resulted in stable disease in a patient with glioblastoma (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588). | detail... |
Unknown unknown | neuroendocrine tumor | not applicable | Everolimus + Vorolanib | Phase I | Actionable | In a Phase I trial, combination of Vorolanib (X-82) and Afinitor (everolimus) resulted in stable disease ranging from 3-23 months in 10 patients with neuroendocrine tumors (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01784861 | Phase Ib/II | Everolimus + Vorolanib | VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors | Terminated | USA | 0 |